ReviewAustralian prescriber2022
Therapeutics for rheumatic fever and rheumatic heart disease.
Review in Australian prescriber, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Acute Rheumatic Fever Beyond Childhood: Case Series of Adult Recurrence and Atypical Manifestations.Cureus · 2026Article
- The "Cairo Accord"- towards the eradication of RHD: revisited (2026).Frontiers in cardiovascular medicine · 2026Review
- Sydenham's Chorea as the Sole Presenting Symptom of Acute Rheumatic Fever in a 14-Year-Old Boy: A Case Report.Clinical medicine insights. Case reports · 2026Article
- Prevalence, types, maternal and perinatal outcomes of cardiac disease in pregnancy at a tertiary Hospital in the Eastern Cape, South Africa.Journal of the colleges of medicine of South Africa · 2026Article
- Epigenetic advances in rheumatic heart disease.Journal of translational autoimmunity · 2025Review
- Adherence to benzathine penicillin prophylaxis and associated factors in patients with rheumatic heart disease attending two public hospitals in Bahir dar, Ethiopia.BMC cardiovascular disorders · 2025Article
- Acute Rheumatic Fever in a Low Prevalence Setting.JACC. Case reports · 2025Article
- Polymeric Heart Valves: Do They Represent a Reliable Alternative to Current Prosthetic Devices?Polymers · 2025Review
- Article
- Rheumatic fever and long-term use of benzathine penicillin as possible risk factors for extensive macular atrophy with pseudodrusen in a Brazilian cohort.International journal of retina and vitreous · 2024Article
- Review
- Article
- Knowledge and Attitude of Rheumatic Fever and Rheumatic Heart Disease Among the Makkah City Population, Saudi Arabia.Cureus · 2024Article
- Outcomes of possible and probable rheumatic fever: A cohort study using northern Australian register data, 2013-2019.PLOS global public health · 2024Article
- The aetiology and incidence of infective endocarditis in people living with rheumatic heart disease in tropical Australia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- The Role of Inflammation and Oxidative Stress in Rheumatic Heart Disease.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goals of acute rheumatic fever therapy are to relieve symptoms, mitigate cardiac valve damage and eradicate streptococcal infection. Preventing future recurrences requires long-term secondary antibiotic prophylaxis and ongoing prevention of Streptococcus pyogenes (group A streptococcus) infections The recommended regimen for secondary prophylaxis comprises benzathine benzylpenicillin G intramuscular injections every four weeks. For patients with non-severe or immediate penicillin hypersensitivity, use erythromycin orally twice daily The goals of therapy for rheumatic heart disease are to prevent progression and optimise cardiac function. Secondary antibiotic prophylaxis can reduce the long-term severity of rheumatic heart disease Patients with rheumatic heart disease, including those receiving benzathine benzylpenicillin G prophylaxis, should receive amoxicillin prophylaxis before undergoing high-risk dental or surgical procedures. If they have recently been treated with a course of penicillin or amoxicillin, or have immediate penicillin hypersensitivity, clindamycin is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.